NALCN and cancer: The results revealed that the expression of NALCN was correlated with 6 immune subtypes in 14 cancer types, including BLCA, BRCA, CESC, COAD, HNSC, LGG, LIHC, LUAD, LUSC, mesothelioma (MESO), PCPG, prostate adenocarcinoma (PRAD), STAD, and UCEC (Figure 5A).